3 recruiting, 2 active not recruiting, 2 terminated, 1 not yet recruiting. 4 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Metastatic Mucosal Melanoma: new trials by email Literature Review of Metastatic Mucosal Melanoma trials Research Report on Metastatic Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Acral Melanoma, Advanced Cutaneous Melanoma | Phase 2 | Recruiting | Emory University | 99 | 2025-10-29 | 2025-11-12 |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Terminated | Emory University | 1 | 2022-10-13 | 2026-04-23 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Binimetinib, Encorafenib, Ipilimumab - Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 112 | 2021-01-06 | 2026-09-15 |
| Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 12 | 2019-06-12 | 2026-01-28 |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Biospecimen Collection, Computed Tomography, Lumbar Puncture - Acral Lentiginous Melanoma, Central Nervous System Melanoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2018-05-02 | 2026-08-19 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
Melanoma (8) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Uveal Melanoma (3) · Brain Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1) · Hodgkin Disease (1) · Meningeal Neoplasms (1) · Nevus (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Nerve Tissue (8) · Neuroectodermal Tumors (8) · Neuroendocrine Tumors (8) · Nevi and Melanomas (8) · Skin Diseases (8) · Skin Neoplasms (8) · Skin and Connective Tissue Diseases (8) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Central Nervous System Neoplasms (3) · Eye Diseases (3)
Nivolumab (6) · Magnetic Resonance Spectroscopy (5) · CTLA-4 Antigen (4) · Ipilimumab (4) · Specimen Handling (4) · Biopsy (2) · pembrolizumab (2) · Interferon alpha-2 (1) · Introns (1) · Radiosurgery (1) · Spinal Puncture (1) · TYRP1 protein, human (1) · binimetinib (1) · encorafenib (1) · poly ICLC (1)
Emory University (2) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1)
United States (7) · Canada (1) · Ireland (1) · Uganda (1)
Isabella C Glitza, MD (1) · Joshua Veatch (1) · Michael Lowe, MD, MA (1) · Mohammad K Khan, MD, PhD (1) · Roxana S. Dronca, M.D. (1) · Sapna Patel (1) · Shailender Bhatia, MD (1) · Zeynep Eroglu (1)
P30CA138292 (2), U10CA180888 (2)